Jaguar Uranium Corp. (NYSEAMERICAN:JAGU – Get Free Report) saw a large decline in short interest during the month of October. As of October 15th, there was short interest totaling 47,480 shares, a decline of 53.0% from the September 30th total of 101,093 shares. Based on an average trading volume of 147,537 shares, the short-interest ratio is currently 0.3 days. Approximately 0.2% of the company’s shares are short sold.
Wall Street Analyst Weigh In
A number of brokerages have commented on JAGU. Roth Capital started coverage on Jaguar Uranium in a research note on Tuesday, July 7th. They issued a “buy” rating and a $3.20 price target on the stock. Zacks Research upgraded Jaguar Uranium to a “hold” rating in a research report on Wednesday, July 8th. One equities research analyst has rated the stock with a Buy rating and one has given a Hold rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $3.20.
Read Our Latest Stock Report on JAGU
Jaguar Uranium Stock Performance
Jaguar Uranium (NYSEAMERICAN:JAGU – Get Free Report) last issued its quarterly earnings data on Wednesday, August 12th. The company reported ($0.04) earnings per share for the quarter. Sell-side analysts expect that Jaguar Uranium will post -1.26 EPS for the current year.
Institutional Investors Weigh In On Jaguar Uranium
A hedge fund recently bought a new stake in Jaguar Uranium stock. Citadel Advisors LLC purchased a new stake in shares of Jaguar Uranium Corp. (NYSEAMERICAN:JAGU – Free Report) during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund purchased 50,000 shares of the company’s stock, valued at approximately $84,000. Citadel Advisors LLC owned 0.25% of Jaguar Uranium at the end of the most recent reporting period.
About Jaguar Uranium
Further Reading
- Five stocks we like better than Jaguar Uranium
- Marvell Eyes a Swing for the AI Networking Fences as Markets Weigh Lumentum Price Tag
- Exxon’s Refining Profits Soared—Did Chevron Get the Same Windfall?
- Eli Lilly’s First Full Medicare Quarter: Is Volume Still Outrunning Price Cuts?
- Oracle’s AI Spending Peak Is in Sight—Can the Stock Recover?
Receive News & Ratings for Jaguar Uranium Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jaguar Uranium and related companies with MarketBeat.com's FREE daily email newsletter.
